Release date- 04092019 - CAMBRIDGE - Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that the New England Journal of Medicine (NEJM) published full results from the double-blind, randomized, placebo-controlled Phase 2 study evaluating SAGE-217 as a treatment for
major depressive disorder (MDD).
The 153 participants had moderate-to-severe
major depressive disorder and were aged 15 to 25 years.
Atypical antipsychotic augmentation in
major depressive disorder: a meta-analysis of placebo-controlled randomized trials.
Major depressive disorder (MDD) is common, recurrent, chronic and disabling.
"These results suggest that resting-state network connectivity may point to some of the brain mechanisms underlying the symptoms of
major depressive disorder," Sheline explains.
Mental health company Magstim reported on Thursday the receipt of approval from the US FDA to include the intermittent Theta Burst Stimulation (iTBS) treatment in combination with its Horizon TMS Therapy systems in patients with
Major Depressive Disorder.
Yet, the moderate overall 11% increased risk of all-cause mortality in adults with treatment-resistant depression, compared with those with non-treatment-resistant
major depressive disorder remains both statistically significant and clinically meaningful, observed Dr.
The present analysis and review of the efficacy and tolerability of switching to vortioxetine includes 3 published studies of patients with
major depressive disorder (MDD) switched from SSRI/SNRI therapy to vortioxetine due to lack of efficacy or tolerability.
9,572,807) for NSI-189, the lead compound in the company's neurogenic small molecule program in development for the treatment of
major depressive disorder.
However, one of the findings from the DSM-5 field trials was that inter-rater reliability for diagnosing
major depressive disorder was very poor.
Major depressive disorder is characterized by persistent low mood, loss of interest, fatigue, and low energy, lasting for at least 2 weeks, and is one of the most common mental illnesses and a major cause of disability worldwide (Moussavi et al.